Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with limited treatment options. Oncolytic virus (OV) therapy exploits replication-competent viruses, including vesicular stomatitis virus (VSV), to preferentially infect and kill malignant cells, while sparing non-malignant cells. We previously showed that human PDAC cell lines are highly heterogeneous in their permissiveness to VSV and other OVs. Although ruxolitinib and other JAK1/2 inhibitors can enhance VSV replication in resistant PDAC cell lines, they also increase the susceptibility of non-malignant cells to OVs. Here, we show that fostamatinib (R788), a spleen tyrosine kinase (SYK) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of chronic immune thrombocytopenia (ITP), spe

SUBMITTER: Catacalos-Goad C 

PROVIDER: S-EPMC12686711 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature